Improvement of insulin sensitivity in insulin resistant subjects during prolonged treatment with the anti‐TNF‐α antibody infliximab
- 17 September 2004
- journal article
- Published by Wiley in European Journal of Clinical Investigation
- Vol. 34 (9) , 641-642
- https://doi.org/10.1111/j.1365-2362.2004.01390.x
Abstract
No abstract availableKeywords
This publication has 9 references indexed in Scilit:
- Apoptotic signal transduction pathways in diabetesBiochemical Pharmacology, 2003
- Infliximab Treatment of Rheumatoid Arthritis and Crohn's DiseaseAnnals of Pharmacotherapy, 2003
- Infliximab treatment for rheumatic disease: clinical and radiological efficacyAnnals of the Rheumatic Diseases, 2002
- Identifying the links between obesity, insulin resistance and β‐cell function: potential role of adipocyte‐derived cytokines in the pathogenesis of type 2 diabetesEuropean Journal of Clinical Investigation, 2002
- Pro-inflammatory cytokines and adipose tissueProceedings of the Nutrition Society, 2001
- No Increased Insulin Sensitivity after a Single Intravenous Administration of a Recombinant Human Tumor Necrosis Factor Receptor: Fc Fusion Protein in Obese Insulin-Resistant PatientsJournal of Clinical Endocrinology & Metabolism, 2000
- Homeostasis model assessment closely mirrors the glucose clamp technique in the assessment of insulin sensitivity: studies in subjects with various degrees of glucose tolerance and insulin sensitivity.Diabetes Care, 2000
- Effects of an Engineered Human Anti–TNF-α Antibody (CDP571) on Insulin Sensitivity and Glycemic Control in Patients With NIDDMDiabetes, 1996
- Adipose Expression of Tumor Necrosis Factor-α: Direct Role in Obesity-Linked Insulin ResistanceScience, 1993